A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR

scientific article

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1026781931
P356DOI10.1038/LEU.2014.217
P932PMC publication ID4320294
P698PubMed publication ID25036192
P5875ResearchGate publication ID264632887

P50authorDolors ColomerQ43096016
Josep NomdedeuQ50238034
Gareth GerrardQ54397742
Anni AggerholmQ57318917
Giovanni MartinelliQ90955283
Claude PreudhommeQ30170087
Andreas HochhausQ37829812
Nicholas CrossQ42628914
P2093author name stringM Jansson
L Wang
F Lin
L Foroni
G Wilson
D-W Kim
G Romeo
L Deprez
D Wren
E Wilkinson
R Ganderton
T Lange
H Andrikovics
A Bench
A Kizilors
B Izzo
B Milner
D A Nymoen
E Gineikienė
E O Leibundgut
F Daraio
G Barbany
G Mitterbauer-Hohendanner
G Nickless
H El Housni
H Emons
H Pfeifer
H Schimmel
H White
J Farrugia
J Ziermann
J-M Cayuela
K M Polakova
K Raudsepp
K Zoi
L Fletcher
M C Müller
M Catherwood
M Nagar
N Boeckx
P A Merle
P Corbisier
P Johnels
P Waits
R Talmaci
R Zadro
S Akiki
S Chudleigh
S Dulucq
S Hayette
S Mazoua
S McCarron
S Trapmann
T Clench
T Jurcek
T Lion
T Pajič
T Sacha
T Touloumenidou
U Ozbek
V H J Van der Velden
V Hall
V Kairisto
P2860cites workDasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaQ43043759
Estimating the uncertainty of stability for matrix CRMsQ43672332
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemiaQ43971962
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaQ44611047
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.Q53042357
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.Q53098953
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.Q53114641
Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease.Q54331600
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratoriesQ58023925
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.Q31012437
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaQ34620246
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.Q35134983
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.Q35561038
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsQ35849776
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Q37026032
Harmonization of molecular monitoring of CML therapy in EuropeQ37587749
Standardisation of molecular monitoring for chronic myeloid leukaemiaQ37644010
Chronic myelogenous leukemia: monitoring response to therapyQ37848207
Standardized definitions of molecular response in chronic myeloid leukemia.Q38002704
BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemiaQ38117928
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.Q39665907
Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendationsQ40095759
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue2
P407language of work or nameEnglishQ1860
P304page(s)369-376
P577publication date2014-07-18
P1433published inLeukemiaQ6534498
P1476titleA certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
P478volume29

Reverse relations

cites work (P2860)
Q37000029An international comparability study on quantification of mRNA gene expression ratios: CCQM-P103.1.
Q40429248Clarity™ digital PCR system: a novel platform for absolute quantification of nucleic acids
Q28066148Current developments in molecular monitoring in chronic myeloid leukemia
Q35107472DNA copy number concentration measured by digital and droplet digital quantitative PCR using certified reference materials
Q26745594Deep molecular responses for treatment-free remission in chronic myeloid leukemia
Q89359928Development and evaluation of armored RNA-based standards for quantification of BCR-ABL1p210/p190 fusion gene transcripts
Q64067404Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
Q91857161Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?
Q42353330Digital PCR, a technique for the future
Q28079008Digital polymerase chain reaction for characterisation of DNA reference materials
Q51821011Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation.
Q39401910Influence of primer & probe chemistry and amplification target on reverse transcription digital PCR quantification of viral RNA.
Q90393398International external quality assurance of JAK2 V617F quantification
Q35603605Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.
Q38481945Molecular genetic evaluation of myeloproliferative neoplasms
Q39027724Molecular monitoring in chronic myeloid leukemia-how low can you go?
Q38392702Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization
Q37696776Molecular techniques for the personalised management of patients with chronic myeloid leukaemia
Q95642294Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
Q38762631Present and future of molecular monitoring in chronic myeloid leukaemia
Q38757317Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.
Q92284305Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
Q40641203Synthetic certified DNA reference material for analysis of human erythropoietin transgene and transcript in gene doping and gene therapy.
Q36094092The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosis
Q98177625Validation of Droplet Digital Polymerase Chain Reaction for Salmonella spp. Quantification
Q40404105Validation of a digital PCR method for quantification of DNA copy number concentrations by using a certified reference material

Search more.